RT Journal Article
T1 Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality.
T2 Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad.
A1 Rivera-Izquierdo, Mario
A1 Valero-Ubierna, María Del Carmen
A1 R-delAmo, Juan Luis
A1 Fernández-García, Miguel Ángel
A1 Martínez-Diz, Silvia
A1 Tahery-Mahmoud, Arezu
A1 Rodríguez-Camacho, Marta
A1 Gámiz-Molina, Ana Belén
A1 Barba-Gyengo, Nicolás
A1 Gámez-Baeza, Pablo
A1 Cabrero-Rodríguez, Celia
A1 Guirado-Ruiz, Pedro Antonio
A1 Martín-Romero, Divina Tatiana
A1 Láinez-Ramos-Bossini, Antonio Jesús
A1 Sánchez-Pérez, María Rosa
A1 Mancera-Romero, José
A1 García-Martín, Miguel
A1 Martín-delosReyes, Luis Miguel
A1 Martínez-Ruiz, Virginia
A1 Jiménez-Mejías, Eladio
K1 COVID
K1 Hospitalizados
K1 Hospitalized
K1 Mortalidad
K1 Mortality
K1 SARS-CoV-2
K1 Tratamientos
K1 Treatments
AB In the last months great efforts have been developed to evaluate the more efficient therapeutic agents in the management of patients with COVID-19. Currently, no specific drug combination has consistently demonstrated an association with mortality. The aim of this study was to assess the pattern of associations observed between the different in-hospital treatments administered to a series of 238 patients admitted for COVID-19 and their relationship with mortality. The electronic medical records of patients that discharged or died from COVID-19 in the Hospital Universitario San Cecilio (Granada, Spain) between March 16 and April 10, 2020 were analysed. From these records, information was obtained on sex, age, comorbidities at admission, clinical information, analytical parameters, imaging tests and empirical treatments used. The outcome variable was the in-hospital mortality. To estimate the associations between the different therapeutic alternatives and the risk of mortality, hazard ratios adjusted for age, sex, previous pathologies and severity at discharge were estimated using Cox regression models. The most frequently used combination of drugs was low molecular weight heparins, hydroxychloroquine, and ritonavir/lopinavir. None of the analysed treatments showed independent association with mortality. The drugs that showed a greater inverse association with mortality were tocilizumab and corticoids. The observed association patterns are consistent with previous literature. It seems necessary to design randomized controlled clinical trials that evaluate the possible protector effect of tocilizumab and corticoids in the risk of mortality for some subgroups of COVID-19 hospitalized patients.
YR 2020
FD 2020-07-09
LK http://hdl.handle.net/10668/16075
UL http://hdl.handle.net/10668/16075
LA en
LA es
DS RISalud
RD Apr 18, 2025